American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1353)
  10. Hematologic Malignancies, Division of (1281)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2579)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM)
    Meeting Abstract

    Touzeau, C.; Beksac, M.; Terpos, E.; Usmani, S. Z.; Krishnan, A. Y.; Nijhof, I. S.; Janowski, W.; Hulin, C.; Grosicki, S.; Delforge, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Khawaja, Mrruh; Naqash, A. R.; Schneider, R.; Shastri, A.; Stahl, M.; Moser, J. C.; Karim, N. F. A.; Madanat, Y.; Jonas, B. A.; Stein, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030
    Meeting Abstract

    Marta, G. N.; Chu, X.; Mukhopadhyay, S.; Abramson, V. G.; Brufsky, A.; Stringer-Reasor, E. M.; Dent, S. F.; Traina, T. A.; Carey, L. A.; Rimawi, M. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tamoxifen for breast cancer prevention among survivors of pediatric lymphoma previously treated with chest radiation: Clinical benefits, harms and tradeoffs
    Meeting Abstract

    Yeh, J. M.; Stein, S. K.; Stratton, K.; Taylor, C. S.; Leisenring, W. M.; Alagoz, O.; Armstrong, G. T.; Hudson, M. M.; Jayasekera, J.; Kurian, A. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study
    Meeting Abstract

    Bhave, M. A.; Jhaveri, K. L.; Kaufman, P. A.; Aftimos, P. G.; Lombard, J. M.; Sideras, K.; Im, S. A.; Ma, C. X.; Lee, K. T.; Kim, S. B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC)
    Meeting Abstract

    Margulis, V.; Kaufman, R. P.; Marcq, G.; Shore, N. D.; Colombel, M.; Uchio, E. M.; Psutka, S. P.; Aller, M.; Rausch, S.; Raventos, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP)
    Meeting Abstract

    Till, B. G.; Jacobson, C. A.; Palomba, M. L.; Abramson, J. S.; Arnason, J.; Locke, F. L.; Caimi, P. F.; Grover, N. S.; Karmali, R.; Suh, H. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • International medical graduates (IMG) representation at international oncology conference meetings
    Meeting Abstract

    Roy, A. M.; Bakouny, Z.; Dizman, N.; Ozay, Z. I.; Lal, B. M.; Nawfal, R.; Eid, M.; Chehade, R. E.; Machaalani, M.; Butt, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) plus /- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd)
    Meeting Abstract

    Pegram, M. D.; Calfa, C.; Chen, C.; CorteĢs Salgado, A.; Heeke, A. L.; Kang, I.; Pistilli, B.; Pohlmann, P. R.; Rugo, H. S.; Saura, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save